Cats With Thyroid Cancer Can Live Years Longer Than Feared, Landmark Study Finds

Thyroid carcinoma is one of the rarest and most feared diagnoses a cat owner can hear, long assumed to carry a grim outlook. A new retrospective study from the Royal Veterinary College in the United Kingdom, published in the journal Veterinary Oncology, now challenges that pessimism with hard clinical data. Reviewing seventeen years of medical records, the researchers found that cats with this uncommon endocrine tumour can survive for years after curative-intent treatment, even when the cancer has already spread. The median tumour-specific survival time in treated cats was never reached during the follow-up period, and median overall survival stood at 795 days, equivalent to more than two years from the moment of diagnosis.

The study team, led by Celia Figueroa and colleagues, combed the hospital database for cats histologically diagnosed with thyroid carcinoma between January 2006 and March 2023. Only cases confirmed by histopathology qualified; diagnoses based on cytology or imaging alone were excluded, as were post-mortem findings and incomplete records. That rigorous filter left twenty-five cats in the final cohort. The median age at diagnosis was twelve years, and mixed-breed cats appeared overrepresented, consistent with earlier case series. No sex predisposition emerged. The tumours themselves were large by any measure, with a median longest axis of 4.4 centimetres and a range stretching from 0.9 to 6.8 centimetres.

The clinical picture that emerged is striking because it so closely mimics ordinary feline hyperthyroidism, a condition affecting a large share of elderly cats. The most common presenting sign was a palpable mass in the ventral neck, seen in 76 percent of cats, alongside weight loss. Nineteen of the twenty-five cats, or 76 percent, had already been treated medically for hyperthyroidism with a thionamide drug for a median of 364 days before the carcinoma was recognised. Fourteen of those cats showed persistently elevated total thyroxine levels despite antithyroid medication or low-dose radioactive iodine, a red flag that the underlying thyroid tissue was not behaving like benign adenomatous hyperplasia.

That treatment history matters because veterinary endocrinologists have long hypothesised that malignant transformation risk increases progressively over time when a toxic goitre is left definitively untreated. The new data lend observational weight to that idea, although the authors are careful to note that biopsy-confirmed progression from adenoma to carcinoma was not available in any of the cats. Five cats had also received low doses of radioactive iodine, between 145 and 185 megabecquerels, before their cancer diagnosis, doses considered insufficient to ablate malignant thyroid tissue. One cat had been managed on an iodine-restricted diet. The practical message for veterinarians is that a firm or enlarging neck mass in a hyperthyroid cat, particularly one refractory to standard medical management, should raise immediate suspicion of carcinoma.

Diagnostic workup in the cohort revealed the strengths and limits of modern veterinary imaging. Computed tomography was performed in ten cats, while fifteen underwent nuclear scintigraphy with technetium-99m, the technique generally regarded as the imaging gold standard for feline thyroid disease because it maps both the location and the functional activity of thyroid tissue. In four of five cats scanned before treatment, scintigraphy was highly suspicious of malignancy, revealing patterns such as linear multifocal uptake, extensive cervical uptake extending into the cranial thorax, and radionuclide accumulation in regional lymph nodes. Yet the authors caution that no scintigraphic feature reliably distinguishes carcinoma from benign disease, and some so-called cold tumours show little uptake at all, meaning complementary imaging remains essential in ambiguous cases.

Under the microscope, follicular carcinoma dominated the histopathologic landscape, accounting for eleven of the fifteen cases available for review by a board-certified anatomic pathologist, followed by two papillary carcinomas. Immunohistochemistry with antibodies against thyroglobulin proved decisive in three diagnostically difficult cases, confirming thyroid origin where salivary gland tumour or C-cell tumour could not otherwise be excluded. The median mitotic count was three per ten high-power fields, though the range was enormous, from zero to thirty-seven, underscoring how biologically heterogeneous these tumours are. Complete surgical excision was achieved in only five cases, and four of those had narrow margins; the remaining ten were incompletely excised, with neoplastic cells extending to the inked resection edges.

Metastasis was documented in twelve cats, or 48 percent of the cohort, a figure squarely within the 40 to 71 percent range reported in earlier necropsy-based studies. The regional lymph nodes were by far the most common destination, involved in ten cats, particularly the ipsilateral retropharyngeal nodes, while four cats had distant spread to the lungs or skeletal muscle. Six cats also showed suspected ectopic thyroid tissue on scintigraphy, though histological confirmation was impossible. Remarkably, despite this substantial metastatic burden, the presence of spread did not worsen survival in cats receiving curative-intent treatment, a counterintuitive finding that echoes the more indolent behaviour of many differentiated thyroid cancers in human patients.

Treatment was aggressive in most cases. Twenty-three of the twenty-five cats received curative-intent therapy: thirteen underwent thyroidectomy alone, nine had surgery followed by high-dose radioactive iodine at a uniform 1100 megabecquerels, and one received high-dose radioactive iodine as the sole modality. Hyperthyroidism resolved in seventeen of twenty-two assessable cats after treatment, or 77 percent. Nine cats needed adjuvant radioactive iodine because of incomplete excision, metastasis, or persistent hyperthyroidism after surgery. Complications were relatively uncommon: four surgical cats developed laryngeal paralysis, hypocalcaemia, or both, all after bilateral thyroidectomy, and one cat was euthanised following refractory hypocalcaemia. Two cats treated with radioactive iodine developed acute kidney injury, one of them fatally, a reminder that reduced glomerular filtration is the principal risk of this otherwise well-tolerated therapy.

The survival statistics are the study’s headline contribution. With a median follow-up of 266 days among the eighteen cats with outcome data, thirteen cats had died or been euthanised, but only five of those deaths were tumour-related, including two from treatment complications. Median overall survival was 795 days, with a 95 percent confidence interval of 503 to 1086 days, while median tumour-specific survival was not reached at all, with observed values extending to 1991 days. Cats treated with surgery followed by high-dose radioactive iodine lived numerically longer than those treated with surgery alone, 946 days versus 590 days, though the difference did not reach statistical significance. No clinical or histological variable, including thyroxine concentration, metastasis status, mitotic count, necrosis, mineralisation, or lymphovascular invasion, was significantly associated with survival in the multivariable model.

The authors acknowledge the inherent limits of a retrospective, single-centre design with a small cohort and non-standardised staging and treatment decisions. Statistical power was low, and outcome data for the two palliatively treated cats were too sparse for meaningful comparison. Even so, the study delivers a clear and hopeful message: feline thyroid carcinoma, though often large and frequently metastatic at diagnosis, behaves more like a chronic disease than an acute killer when treated decisively. For the growing population of elderly cats managed long-term with antithyroid drugs, the findings argue for vigilance, thorough staging, and early referral, because surgery and high-dose radioactive iodine, alone or in combination, can buy these patients years of good-quality life.

Subject of Research: Clinical features, treatment and survival outcomes of feline thyroid carcinoma

Article Title: Clinico-pathological features and outcome of cats with thyroid carcinoma

Article References: Figueroa, C., Yale, A. D., Syme, H., Yaffy, D., Harsum, G., & Guillén, A. (2025). Clinico-pathological features and outcome of cats with thyroid carcinoma. Veterinary Oncology, 2(1), Article 20. https://doi.org/10.1186/s44356-025-00033-4

Image Credits: AI Generated

DOI: 10.1186/s44356-025-00033-4

Keywords: feline thyroid carcinoma, hyperthyroidism, thyroidectomy, high-dose radioactive iodine, veterinary oncology, metastasis, follicular carcinoma, papillary carcinoma, scintigraphy, total thyroxine, cat survival, histopathology